Amantadine Hydrochloride Patent Expiration

Amantadine Hydrochloride is used for managing motor complications in patients with Parkinson's disease receiving levodopa-based therapy. It was first introduced by Endo Pharmaceuticals Inc in its drug Symmetrel on Approved Prior to Jan 1, 1982. Other drugs containing Amantadine Hydrochloride are Osmolex Er, Gocovri. 33 different companies have introduced drugs containing Amantadine Hydrochloride.


Amantadine Hydrochloride Patents

Given below is the list of patents protecting Amantadine Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Gocovri US11065213 Amantadine compositions and preparations thereof Aug 23, 2038 Supernus Pharms
Gocovri US11077073 Methods of using amantadine compositions Aug 23, 2038 Supernus Pharms
Gocovri US12233033 Amantadine compositions, preparations thereof, and methods of use Aug 23, 2038 Supernus Pharms
Osmolex Er US10213393 Composition and method for treating neurological disease Feb 15, 2038 Supernus Pharms
Osmolex Er US10213394 Composition and method for treating neurological disease Feb 15, 2038 Supernus Pharms
Osmolex Er US10500170 Composition and method for treating neurological disease Feb 15, 2038 Supernus Pharms
Osmolex Er US10500171 Composition and method for treating neurological disease Feb 15, 2038 Supernus Pharms
Osmolex Er US10500172 Composition and method for treating neurological disease Feb 15, 2038 Supernus Pharms
Osmolex Er US10512617 Composition and method for treating neurological disease Feb 15, 2038 Supernus Pharms
Osmolex Er US11890261 Composition and method for treating neurological disease Feb 15, 2038 Supernus Pharms
Gocovri US10154971 Methods of administering amantadine Dec 04, 2034 Supernus Pharms
Gocovri US10646456 Methods of administering amantadine Jun 17, 2034 Supernus Pharms
Gocovri US11903908 Methods of administering amantadine Jun 17, 2034 Supernus Pharms
Gocovri US11197835 Method of administering amantadine prior to a sleep period Dec 02, 2030 Supernus Pharms
Gocovri US8741343 Method of administering amantadine prior to a sleep period Dec 02, 2030 Supernus Pharms
Gocovri US9867791 Method of administering amantadine prior to a sleep period Dec 02, 2030 Supernus Pharms
Gocovri US9867792 Method of administering amantadine prior to a sleep period Dec 02, 2030 Supernus Pharms
Gocovri US9867793 Method of administering amantadine prior to a sleep period Dec 02, 2030 Supernus Pharms
Gocovri US9877933 Method of administering amantadine prior to a sleep period Dec 02, 2030 Supernus Pharms
Osmolex Er US8252331 Osmotic device containing amantadine and an osmotic salt Mar 13, 2030 Supernus Pharms
Gocovri US8389578 Composition and method for treating neurological disease Jan 22, 2028 Supernus Pharms
Osmolex Er US8389578 Composition and method for treating neurological disease Jan 22, 2028 Supernus Pharms
Osmolex Er US8574626 Osmotic device containing amantadine and an osmotic salt Nov 28, 2025 Supernus Pharms
Gocovri US8796337 Composition and method for treating neurological disease Nov 23, 2025 Supernus Pharms
Gocovri US8889740 Composition and method for treating neurological disease Nov 23, 2025 Supernus Pharms
Gocovri US8895614 Composition and method for treating neurological disease Nov 23, 2025 Supernus Pharms
Gocovri US8895615 Composition and method for treating neurological disease Nov 23, 2025 Supernus Pharms
Gocovri US8895616 Composition and method for treating neurological disease Nov 23, 2025 Supernus Pharms
Gocovri US8895617 Composition and method for treating neurological disease Nov 23, 2025 Supernus Pharms
Gocovri US8895618 Composition and method for treating neurological disease Nov 23, 2025 Supernus Pharms
Osmolex Er US8796337 Composition and method for treating neurological disease Nov 23, 2025 Supernus Pharms
Osmolex Er US8889740 Composition and method for treating neurological disease Nov 23, 2025 Supernus Pharms
Osmolex Er US8895614 Composition and method for treating neurological disease Nov 23, 2025 Supernus Pharms
Osmolex Er US8895615 Composition and method for treating neurological disease Nov 23, 2025 Supernus Pharms
Osmolex Er US8895616 Composition and method for treating neurological disease Nov 23, 2025 Supernus Pharms
Osmolex Er US8895617 Composition and method for treating neurological disease Nov 23, 2025 Supernus Pharms
Osmolex Er US8895618 Composition and method for treating neurological disease Nov 23, 2025 Supernus Pharms
Osmolex Er US8987333 Composition and method for treating neurological disease Nov 23, 2025 Supernus Pharms
Osmolex Er US9072697 Composition and method for treating neurological disease Nov 23, 2025 Supernus Pharms
Osmolex Er USRE39069 Multi-layered osmotic device May 29, 2018

(Expired)

Supernus Pharms



Amantadine Hydrochloride's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Amantadine Hydrochloride Generic API Manufacturers

Several generic applications have been filed for Amantadine Hydrochloride. The first generic version for Amantadine Hydrochloride was by Upsher Smith Laboratories Llc and was approved on Aug 5, 1986. And the latest generic version is by Zhejiang Jutai Pharmaceutical Co Ltd and was approved on Sep 26, 2024.

Given below is the list of companies who have filed for Amantadine Hydrochloride generic, along with the locations of their manufacturing plants worldwide.